STUDY ON THE SITUATION AND CHARACTERISTICS OF HEART FAILURE WITH PRESERVED EJECTION FRACTION IN HYPERTENSIVE PATIENTS AT CARDIOVASCULAR DEPARTMENT CAN THO GENERAL HOSPITAL IN 2019-2020
Main Article Content
Abstract
Background: Hypertension is a common disease in clinical practice leading to many dangerous complications, of which heart failure is one of the ultimate consequences of hypertension. Heart failure with preserved ejection fraction is the most common cardiovascular related condition in hypertensive patients and accounts for 40-70% of heart failure cases. Materials and methods: A cross sectional descriptive study of heart failure characteristics in 287 patients with primary hypertension at Can Tho General Hospital in 2019-2020. Results: The rate of heart failure with preserved ejection fraction in patient with primary hypertension was 12.5%. Average age was 74.44 ± 10.97 years, 61.1% were female, hypertension grade 2 and 3 accounted for 94.4% and 63.9% had hypertension duration ≥5 years. In which age ≥75 years, duration of hypertension ≥5 years and hypertension grade 3 were factors related to heart failure with preserved ejection fraction. Dyspnea on effort was the most common symptom, accounted for 97.2%. The left ventricular ejection fraction mean was 65.06 ± 7.67%, median NT-proBNP was 1607.5pg/mL with minimum value was 137.6pg/mL and maximum were 32651pg/mL. Left ventricular morphology abnormal was 66.7% and left atrial enlargement in 100% of cases. 8.3% of patients had E/A ratio ≥2 and 13.8% had TR vel >2.8m/s. Conclusion: Heart failure with preserved ejection fraction was common in older patients (especially over 75 years), hypertension duration more than 5 years and hypertension grade 3, dyspnea and left atrial enlargement was the most common sign.
Article Details
Keywords
Primary hypertension, heart failure with preserved ejection fraction
References
2. Bùi Hữu Minh Trí, Dương Hồng Chương, Trương Hữu Có và cộng sự (2014), “Chẩn đoán, điều trị & diễn tiến lâm sàng suy tim có phân suất tống máu bảo tồn tại Bệnh viện Tim mạch An Giang”, [Internet], 25/07/2014.
3. Amil M. Shah, MD MPH, Sanjiv J. Shah, et al. (2014), “Baseline Findings from the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial”, Circ Heart Fail September, 7(5), pp.740–751.
4. Chioncel O, Lainscak M, Seferovic PM, et al. (2017), “Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry”, Eur J Heart Fail, 19(12), pp.1574-1585.
5. Fang, Alex Pui-Wai Lee, and Cheuk-Man Yu (2014), “Left atrial function in heart failure with impaired and preserved ejection fraction”, Curr Opin Cardiol, 29, pp.430-436.
6. Frank R, Felix H, Ge Jin, et al. (2015), “Myocardial Hypertrophy and Its Role in Heart Failure with Preserved Ejection Fraction”, J Appl Physiol, 119(10), pp.1233–1242.
7. Ho, J. E. et al. (2016), “Predicting heart failure with preserved and reduced ejection fraction:
the International Collaboration on Heart Failure Subtypes”, Circ. Heart Fail. 9, e003116.
8. Magyar K, Gal R, Riba A, et al. (2015), “From hypertension to heart failure”, World J Hypertens, 5(2), pp.85- 92.
9. Michael R.Zile and William C. Little (2015), “Heart failure with preserved ejection fraction”, Braunwalds Heart Diseas: A textbook of cardiovascular medicine, 10th edition.
10. Owan TE, Hodge DO, Herges RM, et al. (2006), “Trends in prevalence and outcome of heart failure with preserved ejection fraction”, N Engl J Med, 355(3), pp.251-259.
11. Rolf Wachter, Sanjiv J. Shah, Martin R. Cowie, et al. (2020), “Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial”, ESC Heart Failure, 7, pp.856-864.
12. Sacha Bhatia, M.D., M.B.A., et al. (2006), “Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study”, N Engl J Med, 355:260-9.
13. Scott D. Solomon, M.D., John J.V. McMurray, et al. (2019), “Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction”, N Engl J Med, 381:1609-1620.
14. Tschope C., Kasner M., Westermann D. (2005), The role of NT-proBNP in the diagnostics of isolated diastolic function: correlation with echocardiographic and invasive measurements, European Heart Journal, 26, pp.2277-2284.